Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study.

Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L.

Oncoimmunology. 2019 Nov 5;9(1):1682383. doi: 10.1080/2162402X.2019.1682383. eCollection 2020.

2.

[Facial edema and erythroderma in a 54 year-old woman].

Mourguet M, Lajaunie R, Schouler M, Godart M, Bonnet D, Riffaud L, Lamant L, Alric L, Rossi B.

Rev Med Interne. 2020 Jan 24. pii: S0248-8663(19)30619-8. doi: 10.1016/j.revmed.2019.08.002. [Epub ahead of print] French. No abstract available.

PMID:
31987672
3.

Outcomes of 4 years of molecular genetic diagnosis on a panel of genes involved in premature aging syndromes, including laminopathies and related disorders.

Grelet M, Blanck V, Sigaudy S, Philip N, Giuliano F, Khachnaoui K, Morel G, Grotto S, Sophie J, Poirsier C, Lespinasse J, Alric L, Calvas P, Chalhoub G, Layet V, Molin A, Colson C, Marsili L, Edery P, Lévy N, De Sandre-Giovannoli A.

Orphanet J Rare Dis. 2019 Dec 11;14(1):288. doi: 10.1186/s13023-019-1189-z.

4.

Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA.

Abravanel F, Lhomme S, Trémeaux P, Migueres M, Harter A, Haslé C, Bruel P, Alric L, Métivier S, Raymond S, Izopet J.

Diagn Microbiol Infect Dis. 2020 Feb;96(2):114946. doi: 10.1016/j.diagmicrobio.2019.114946. Epub 2019 Nov 16.

PMID:
31771903
5.

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus: genotype 4 infection: a randomized study.

Asselah T, Pol S, Hezode C, Loustaud-Ratti V, Leroy V, Ahmed SNS, Ozenne V, Bronowicki JP, Larrey D, Tran A, Alric L, Nguyen-Khac E, Robertson MN, Hanna GJ, Brown D, Asante-Appiah E, Su FH, Hwang P, Hall JD, Guidoum A, Hagen K, Haber BA, Talwani R, Serfaty L.

Liver Int. 2019 Nov 25. doi: 10.1111/liv.14313. [Epub ahead of print]

PMID:
31765046
6.

Whipple's disease: diagnosis and predictive factors of relapse.

Ferrieres L, Laroche M, Bonnet D, Alric L.

Eur J Gastroenterol Hepatol. 2020 Mar;32(3):325-328. doi: 10.1097/MEG.0000000000001611.

PMID:
31764405
7.

[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update].

Comont T, Belliere J, Sibaud V, Alric L, Meyer N, Mazières J, Caron P, Acket B, Michot JM, Beyne-Rauzy O, Lambotte O.

Rev Med Interne. 2020 Jan;41(1):37-45. doi: 10.1016/j.revmed.2019.09.005. Epub 2019 Oct 24. French.

PMID:
31668882
8.

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients.

Protin C, Abravanel F, Alric L, Tavitian S, Obéric L, Izopet J, Martin-Blondel G, Ysebaert L.

Open Forum Infect Dis. 2019 Jul 28;6(9):ofz345. doi: 10.1093/ofid/ofz345. eCollection 2019 Sep.

9.

Active thrombin produced by the intestinal epithelium controls mucosal biofilms.

Motta JP, Denadai-Souza A, Sagnat D, Guiraud L, Edir A, Bonnart C, Sebbag M, Rousset P, Lapeyre A, Seguy C, Mathurine-Thomas N, Galipeau HJ, Bonnet D, Alric L, Buret AG, Wallace JL, Dufour A, Verdu EF, Hollenberg MD, Oswald E, Serino M, Deraison C, Vergnolle N.

Nat Commun. 2019 Jul 19;10(1):3224. doi: 10.1038/s41467-019-11140-w.

10.

Apple core pattern in skeletal sarcoidosis.

Maquet J, Couture G, Alric L.

Joint Bone Spine. 2020 Jan;87(1):85. doi: 10.1016/j.jbspin.2019.06.011. Epub 2019 Jul 4. No abstract available.

PMID:
31279741
11.

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.

von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V.

J Hepatol. 2019 Sep;71(3):465-472. doi: 10.1016/j.jhep.2019.04.022. Epub 2019 May 18.

PMID:
31108159
12.

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.

Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L, Piroth L, Bouchaud O, Katlama C, Morlat P, Lascoux-Combe C, Gervais A, Naqvi A, Rosenthal E, Garipuy D, Barange K, Esterle L, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1387-1396. doi: 10.1097/MEG.0000000000001408.

PMID:
31033848
13.

No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents.

Del Bello A, Abravanel F, Alric L, Lavayssiere L, Lhomme S, Bellière J, Izopet J, Kamar N.

Transpl Infect Dis. 2019 Aug;21(4):e13093. doi: 10.1111/tid.13093. Epub 2019 Apr 30.

PMID:
30972874
14.

Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification.

Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES.

Open Forum Infect Dis. 2019 Feb 22;6(3):ofz076. doi: 10.1093/ofid/ofz076. eCollection 2019 Mar.

15.

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group.

BMC Infect Dis. 2019 Apr 2;19(1):300. doi: 10.1186/s12879-019-3923-5.

16.

Increased CXCR3+ T Cells Impairs Recruitment of T-Helper Type 17 Cells via Interferon γ and Interleukin 18 in the Small Intestine Mucosa During Treated HIV-1 Infection.

Loiseau C, Requena M, Nayrac M, Mavigner M, Cazabat M, Iscache AL, Carrere N, Suc B, Alric L, Izopet J, Delobel P.

J Infect Dis. 2019 Jul 31;220(5):830-840. doi: 10.1093/infdis/jiz123.

PMID:
30880342
17.

Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.

Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P.

J Hepatol. 2019 May;70(5):831-838. doi: 10.1016/j.jhep.2018.12.036. Epub 2019 Mar 14.

PMID:
30879789
18.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group.

Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.

PMID:
30768988
19.

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort.

Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.

PMID:
30765123
20.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin MA, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G, Bouchaud O, Gervais-Hasenknoff A, Goujard C, Piroth L, Zucman D, Dominguez S, Raffi F, Alric L, Bani-Sadr F, Lascoux-Combe C, Garipuy D, Miailhes P, Vittecoq D, Duvivier C, Aumaître H, Neau D, Morlat P, Dabis F, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

PLoS One. 2019 Jan 25;14(1):e0211286. doi: 10.1371/journal.pone.0211286. eCollection 2019.

21.

IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.

Alaeddine M, Prat M, Poinsot V, Gouazé-Andersson V, Authier H, Meunier E, Lefèvre L, Alric C, Dardenne C, Bernad J, Alric L, Segui B, Balard P, Couderc F, Couderc B, Pipy B, Coste A.

Cancer Immunol Res. 2019 Feb;7(2):321-334. doi: 10.1158/2326-6066.CIR-18-0213. Epub 2019 Jan 4.

22.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
23.

Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients.

Poizot-Martin I, Rosenthal E, Gilbert C, Cano CE, Simon A, Lascoux-Combe C, Alric L, Gervais A, Neau D, Esterle L, Salmon D, Sogni P, Wittkop L; ANRS CO13 HEPAVIH Study Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):461-466. doi: 10.1097/QAI.0000000000001940.

PMID:
30570526
24.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

25.

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.

Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, Di Rocco A, Ferrari A, Farina L, Pirisi M, Piazza F, Loustaud-Ratti V, Arcari A, Marino D, Sica A, Goldaniga M, Rusconi C, Gentile M, Cencini E, Benanti F, Rumi MG, Ferretti VV, Grossi P, Gotti M, Sciarra R, Tisi MC, Cano I, Zuccaro V, Passamonti F, Arcaini L.

Oncologist. 2019 Aug;24(8):e720-e729. doi: 10.1634/theoncologist.2018-0331. Epub 2018 Dec 14.

26.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.

27.

Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group.

J Viral Hepat. 2019 Mar;26(3):384-396. doi: 10.1111/jvh.13029. Epub 2019 Jan 16.

PMID:
30380181
28.

Performance of a commercial assay for detecting and quantifying HEV RNA in faeces.

Abravanel F, Lacipière A, Lhomme S, Dubois M, Minier L, Peron JM, Alric L, Kamar N, Izopet J.

J Clin Virol. 2018 Dec;109:1-5. doi: 10.1016/j.jcv.2018.10.003. Epub 2018 Oct 10.

PMID:
30336371
29.

Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis.

Mourguet M, Chauveau D, Faguer S, Ruidavets JB, Béjot Y, Ribes D, Huart A, Alric L, Balardy L, Astudillo L, Adoue D, Sailler L, Pugnet G.

J Autoimmun. 2019 Jan;96:134-141. doi: 10.1016/j.jaut.2018.09.004. Epub 2018 Sep 17.

PMID:
30236485
30.

Impact of micronutrient deficiency & malnutrition in systemic sclerosis: Cohort study and literature review.

Dupont R, Longué M, Galinier A, Cinq Frais C, Ingueneau C, Astudillo L, Arlet P, Adoue D, Alric L, Prévot G, Cabarrou B, Sailler L, Pugnet G.

Autoimmun Rev. 2018 Nov;17(11):1081-1089. doi: 10.1016/j.autrev.2018.05.010. Epub 2018 Sep 10. Review.

PMID:
30213693
31.

Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.

Desbois AC, Biard L, Addimanda O, Lambert M, Hachulla E, Launay D, Ackermann F, Pérard L, Hot A, Maurier F, Mausservey C, Bernard F, Noel N, Alric L, Mirault T, Cohen F, Boussouar S, Resche-Rigon M, Cacoub P, Saadoun D.

Clin Immunol. 2018 Dec;197:54-59. doi: 10.1016/j.clim.2018.08.004. Epub 2018 Aug 18.

PMID:
30125675
32.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.

PMID:
30031138
33.

Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.

Garnier C, Ribes D, Chauveau D, Huart A, Pugnet G, Adoue D, Prevot G, Alric L, Delobel P, Derumeaux H, Mengelle C, Sailler L, Moulis G.

J Rheumatol. 2018 Nov;45(11):1541-1548. doi: 10.3899/jrheum.180310. Epub 2018 Jul 15.

PMID:
30008461
34.

Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism.

Sébert M, Denadai-Souza A, Quaranta M, Racaud-Sultan C, Chabot S, Lluel P, Monjotin N, Alric L, Portier G, Kirzin S, Bonnet D, Ferrand A, Vergnolle N.

Br J Pharmacol. 2018 Sep;175(18):3656-3668. doi: 10.1111/bph.14430. Epub 2018 Aug 7.

35.

Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis.

Cacoub P, Si Ahmed SN, Ferfar Y, Pol S, Thabut D, Hezode C, Alric L, Comarmond C, Ragab G, Quartuccio L, Hegazy M, Poynard T, Resche Rigon M, Saadoun D.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):518-526. doi: 10.1016/j.cgh.2018.05.021. Epub 2018 May 29.

PMID:
29857143
36.

Hepatitis E virus-associated cryoglobulinemia in solid-organ-transplant recipients.

Marion O, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, Alric L, Faguer S, Izopet J, Kamar N.

Liver Int. 2018 Dec;38(12):2178-2189. doi: 10.1111/liv.13894. Epub 2018 Jun 14.

PMID:
29845733
37.

Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease.

Denadai-Souza A, Bonnart C, Tapias NS, Marcellin M, Gilmore B, Alric L, Bonnet D, Burlet-Schiltz O, Hollenberg MD, Vergnolle N, Deraison C.

Sci Rep. 2018 May 18;8(1):7834. doi: 10.1038/s41598-018-26282-y.

38.

CCDC115-CDG: A new rare and misleading inherited cause of liver disease.

Girard M, Poujois A, Fabre M, Lacaille F, Debray D, Rio M, Fenaille F, Cholet S, Ruel C, Caussé E, Selves J, Bridoux-Henno L, Woimant F, Dupré T, Vuillaumier-Barrot S, Seta N, Alric L, de Lonlay P, Bruneel A.

Mol Genet Metab. 2018 Jul;124(3):228-235. doi: 10.1016/j.ymgme.2018.05.002. Epub 2018 May 9.

PMID:
29759592
39.

Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.

Alric L, Ollivier-Hourmand I, Bérard E, Hillaire S, Guillaume M, Vallet-Pichard A, Bernard-Chabert B, Loustaud-Ratti V, Bourlière M, de Ledinghen V, Fouchard-Hubert I, Canva V, Minello A, Nguyen-Khac E, Leroy V, Saadoun D, Trias D, Pol S, Kamar N.

Kidney Int. 2018 Jul;94(1):206-213. doi: 10.1016/j.kint.2018.02.019. Epub 2018 May 5.

PMID:
29735308
40.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.

PMID:
29729258
41.

Severe liver failure rather than cirrhosis is associated with mortality in patients with infectious endocarditis: a retrospective case-control study.

Allaire M, Cadranel JD, Bureau C, Zerkly S, Thévenot T, Garioud A, Cacoub P, Macaigne G, Alric L, Jouannaud V, Lison H, Chagneau-Derrode C, Pariente A, Pe Combining Acute Accent Laquier ACGAS, Bourlie Combining Grave Accent Re M, Causse X, Nousbaum JB, Dumortier JCAAR, Louvet A, Rosa-He Combining Acute Accent Zode I, Ganne-Carrie Combining Acute Accent N, Chentouh R, Sfaxi A, Gournay JCAAR, Blasco-Perrin HCAALCGAN, Antonini T, Spahr L, Bronowicki JP, Silvain C, Di Martino V, Grange JD, Denis J, Dupont K, Iaria P, Ollivier-Hourmand I, Dao T; French association of gastroenterologist and hepatologist from primary hospital (ANGH).

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1216-1223. doi: 10.1097/MEG.0000000000001155.

PMID:
29727379
42.

Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients.

Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, Jego P, Busato F, Cabon M, Dhote R, Estibaliz L, Koné-Paut I, Landron C, Lavigne C, Lioger B, Michaud M, Ruivard M, Sacre K, Gottenberg JE, Gaches F, Goulenok T, Salvarani C, Cacoub P, Fain O, Saadoun D; French Takayasu network.

J Autoimmun. 2018 Jul;91:55-60. doi: 10.1016/j.jaut.2018.04.002. Epub 2018 Apr 17.

PMID:
29678346
43.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10.

PMID:
29663511
44.

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.

PMID:
29653647
45.

Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.

Pol S, Marion O, Vallet-Pichard A, Meritet JF, Sauné K, Alric L, Kamar N.

Transpl Infect Dis. 2018 Jun;20(3):e12864. doi: 10.1111/tid.12864. Epub 2018 Mar 25.

PMID:
29512231
46.

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group.

HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7.

PMID:
29214737
47.

Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection.

Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S, Aneja J, Alric L, Donfield SM, Cramp ME, Khakoo SI, Tobler LH, Busch M, Alexander GJ, Rosen HR, Edlin BR, Segal FP, Lauer GM, Thomas DL, Daly MJ, Chung RT, Kim AY.

Sci Rep. 2017 Nov 20;7(1):15843. doi: 10.1038/s41598-017-16011-2.

48.

Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.

de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM.

Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916.

49.

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F.

J Hepatol. 2018 Mar;68(3):595-597. doi: 10.1016/j.jhep.2017.09.019. Epub 2017 Oct 4. No abstract available.

PMID:
28987520
50.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, Maliakkal B, Agarwal K, Hassanein T, Weilert F, Lee SS, Kort J, Lovell SS, Liu R, Lin CW, Pilot-Matias T, Krishnan P, Mensa FJ.

Hepatology. 2018 Feb;67(2):514-523. doi: 10.1002/hep.29541. Epub 2018 Jan 4.

Supplemental Content

Support Center